The U.S. Food and Drug Administration has approved a fifth vaccine for protection against swine flu. As with the four previous vaccines, ID Biomedical Corp. will manufacture its H1N1 vaccine using the established, egg-based manufacturing process used for producing seasonal flu vaccine.
Potential side effects of the vaccine are expected to be similar to those of the seasonal and other swine flu. The most common side effect is soreness at the injection site. Others may include mild fever, body aches and fatigue for a few days after the inoculation, the FDA said.
As with any medical product, unexpected or rare serious adverse events may occur and government agencies are working together to monitor the H1N1 vaccination program.
The new vaccine will contain thimerosal, a preservative that contains mercury.